Literature DB >> 25715406

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.

Jessica Bordini1, Maria Teresa Sabrina Bertilaccio2, Maurilio Ponzoni3, Isabella Fermo4, Marta Chesi5, P Leif Bergsagel5, Clara Camaschella6, Alessandro Campanella7.   

Abstract

Multiple myeloma is a malignant disorder characterized by bone marrow proliferation of plasma cells and by overproduction of monoclonal immunoglobulin detectable in the sera (M-spike). Anemia is a common complication of multiple myeloma, but the underlying pathophysiological mechanisms have not been completely elucidated. We aimed to identify the different determinants of anemia using the Vk*MYC mouse, which spontaneously develops an indolent bone marrow localized disease with aging. Affected Vk*MYC mice develop a mild normochromic normocytic anemia. We excluded the possibility that anemia results from defective erythropoietin production, inflammation or increased hepcidin expression. Mature erythroid precursors are reduced in Vk*MYC bone marrow compared with wild-type. Malignant plasma cells express the apoptogenic receptor Fas ligand and, accordingly, active caspase 8 is detected in maturing erythroblasts. Systemic iron homeostasis is not compromised in Vk*MYC animals, but high expression of the iron importer CD71 by bone marrow plasma cells and iron accumulation in bone marrow macrophages suggest that iron competition takes place in the local multiple myeloma microenvironment, which might contribute to anemia. In conclusion, the mild anemia of the Vk*MYC model is mainly related to the local effect of the bone marrow malignant clone in the absence of an overt inflammatory status. We suggest that this reproduces the initial events triggering anemia in patients. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25715406      PMCID: PMC4450630          DOI: 10.3324/haematol.2014.118000

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  26 in total

1.  Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis.

Authors:  P Musto; A Falcone; G D'Arena; P R Scalzulli; R Matera; M M Minervini; G F Lombardi; S Modoni; A Longo; M Carotenuto
Journal:  Eur J Haematol       Date:  1997-05       Impact factor: 2.997

2.  The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.

Authors:  D Cella
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

Review 3.  Anemia of chronic disease.

Authors:  Guenter Weiss; Lawrence T Goodnough
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 4.  Hepcidin and iron regulation, 10 years later.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2011-02-23       Impact factor: 22.113

5.  Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin.

Authors:  Mitchell D Knutson; Mohamed Oukka; Lindsey M Koss; Fikret Aydemir; Marianne Wessling-Resnick
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-21       Impact factor: 11.205

Review 6.  The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia.

Authors:  Stefano Rivella
Journal:  Blood Rev       Date:  2012-04       Impact factor: 8.250

7.  Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.

Authors:  Franco Silvestris; Paola Cafforio; Marco Tucci; Franco Dammacco
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC.

Authors:  K J Wu; A Polack; R Dalla-Favera
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

10.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

View more
  6 in total

1.  Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma.

Authors:  J Bordini; S Galvan; M Ponzoni; M T S Bertilaccio; M Chesi; P L Bergsagel; C Camaschella; A Campanella
Journal:  Leukemia       Date:  2016-11-24       Impact factor: 11.528

2.  Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.

Authors:  Antonella Nai; Aude Rubio; Alessandro Campanella; Ophélie Gourbeyre; Irene Artuso; Jessica Bordini; Aurélie Gineste; Chloé Latour; Céline Besson-Fournier; Herbert Y Lin; Hélène Coppin; Marie-Paule Roth; Clara Camaschella; Laura Silvestri; Delphine Meynard
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

Review 3.  Iron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammation.

Authors:  Manfred Nairz; Igor Theurl; Dominik Wolf; Günter Weiss
Journal:  Wien Med Wochenschr       Date:  2016-08-24

4.  Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.

Authors:  Lanting Liu; Zhen Yu; Hui Cheng; Xuehan Mao; Weiwei Sui; Shuhui Deng; Xiaojing Wei; Junqiang Lv; Chenxing Du; Jie Xu; Wenyang Huang; Shuang Xia; Gang An; Wen Zhou; Xiaoke Ma; Tao Cheng; Lugui Qiu; Mu Hao
Journal:  Sci Rep       Date:  2020-11-25       Impact factor: 4.379

5.  Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies.

Authors:  Jessica Bordini; Federica Morisi; Fulvia Cerruti; Paolo Cascio; Clara Camaschella; Paolo Ghia; Alessandro Campanella
Journal:  Cancers (Basel)       Date:  2020-04-14       Impact factor: 6.639

6.  The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.

Authors:  Małgorzata Banaszkiewicz; Jolanta Małyszko; Krzysztof Batko; Ewa Koc-Żórawska; Marcin Żórawski; Paulina Dumnicka; Artur Jurczyszyn; Karolina Woziwodzka; Aleksandra Maleszka; Marcin Krzanowski; Andrzej Kraśniak; Ryszard Drożdż; Katarzyna Krzanowska
Journal:  Medicina (Kaunas)       Date:  2022-03-11       Impact factor: 2.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.